The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Parkinson's disease therapeutics includes medications and therapies used to manage the symptoms of Parkinson's disease, a neurodegenerative disorder that affects movement and motor control.
The global Parkinson’s Disease Therapeutics market was valued at US$ 2337.8 million in 2023 and is anticipated to reach US$ 3533.7 million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.
The market for Parkinson's disease therapeutics is driven by the increasing prevalence of Parkinson's disease and the demand for symptomatic relief and disease-modifying treatments. The market's growth is also influenced by ongoing research in Parkinson's disease pathophysiology and the development of novel therapeutic approaches.
This report aims to provide a comprehensive presentation of the global market for Parkinson’s Disease Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Parkinson’s Disease Therapeutics.
Report Scope
The Parkinson’s Disease Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Parkinson’s Disease Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Parkinson’s Disease Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
- Abbvie
- Biogen
- Boehringer Ingelheim GmbH
- F. Hoffman-La Roche
- GlaxoSmithKline
- H. Lundbeck A/S
- Impax Labs
- Newron Pharmaceuticals SpA
- Novartis AG
- Orion Corporation
- Teva Pharmaceutical Industries Ltd.
- UCB S.A.
- Livzon Pharmaceutical
- Haisco Pharmaceutical
- Jingxin Pharmaceutical
- Dongcheng Biochemicals
Segment by Type
- Oral
- Transdermal
- Subcutaneous
- Intestinal Infusion
Segment by Application
- Hospitals
- Clinics
- Others
Consumption by Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia)
- Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
- Latin America (Mexico, Brazil, Argentina)
- Middle East & Africa (Turkey, Saudi Arabia, UAE)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Parkinson’s Disease Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Parkinson’s Disease Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral
1.2.3 Transdermal
1.2.4 Subcutaneous
1.2.5 Intestinal Infusion
1.3 Market by Application
1.3.1 Global Parkinson’s Disease Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Parkinson’s Disease Therapeutics Market Perspective (2019-2030)
2.2 Parkinson’s Disease Therapeutics Growth Trends by Region
2.2.1 Global Parkinson’s Disease Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Parkinson’s Disease Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Parkinson’s Disease Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Parkinson’s Disease Therapeutics Market Dynamics
2.3.1 Parkinson’s Disease Therapeutics Industry Trends
2.3.2 Parkinson’s Disease Therapeutics Market Drivers
2.3.3 Parkinson’s Disease Therapeutics Market Challenges
2.3.4 Parkinson’s Disease Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Parkinson’s Disease Therapeutics Players by Revenue
3.1.1 Global Top Parkinson’s Disease Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Parkinson’s Disease Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Parkinson’s Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Parkinson’s Disease Therapeutics Revenue
3.4 Global Parkinson’s Disease Therapeutics Market Concentration Ratio
3.4.1 Global Parkinson’s Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Parkinson’s Disease Therapeutics Revenue in 2023
3.5 Parkinson’s Disease Therapeutics Key Players Head office and Area Served
3.6 Key Players Parkinson’s Disease Therapeutics Product Solution and Service
3.7 Date of Enter into Parkinson’s Disease Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Parkinson’s Disease Therapeutics Breakdown Data by Type
4.1 Global Parkinson’s Disease Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Parkinson’s Disease Therapeutics Forecasted Market Size by Type (2025-2030)
5 Parkinson’s Disease Therapeutics Breakdown Data by Application
5.1 Global Parkinson’s Disease Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Parkinson’s Disease Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Parkinson’s Disease Therapeutics Market Size (2019-2030)
6.2 North America Parkinson’s Disease Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Parkinson’s Disease Therapeutics Market Size by Country (2019-2024)
6.4 North America Parkinson’s Disease Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Parkinson’s Disease Therapeutics Market Size (2019-2030)
7.2 Europe Parkinson’s Disease Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Parkinson’s Disease Therapeutics Market Size by Country (2019-2024)
7.4 Europe Parkinson’s Disease Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Parkinson’s Disease Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Parkinson’s Disease Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Parkinson’s Disease Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Parkinson’s Disease Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Parkinson’s Disease Therapeutics Market Size (2019-2030)
9.2 Latin America Parkinson’s Disease Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Parkinson’s Disease Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Parkinson’s Disease Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Parkinson’s Disease Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Parkinson’s Disease Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Parkinson’s Disease Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Parkinson’s Disease Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbvie
11.1.1 Abbvie Company Detail
11.1.2 Abbvie Business Overview
11.1.3 Abbvie Parkinson’s Disease Therapeutics Introduction
11.1.4 Abbvie Revenue in Parkinson’s Disease Therapeutics Business (2019-2024)
11.1.5 Abbvie Recent Development
11.2 Biogen
11.2.1 Biogen Company Detail
11.2.2 Biogen Business Overview
11.2.3 Biogen Parkinson’s Disease Therapeutics Introduction
11.2.4 Biogen Revenue in Parkinson’s Disease Therapeutics Business (2019-2024)
11.2.5 Biogen Recent Development
11.3 Boehringer Ingelheim GmbH
11.3.1 Boehringer Ingelheim GmbH Company Detail
11.3.2 Boehringer Ingelheim GmbH Business Overview
11.3.3 Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Introduction
11.3.4 Boehringer Ingelheim GmbH Revenue in Parkinson’s Disease Therapeutics Business (2019-2024)
11.3.5 Boehringer Ingelheim GmbH Recent Development
11.4 F. Hoffman-La Roche
11.4.1 F. Hoffman-La Roche Company Detail
11.4.2 F. Hoffman-La Roche Business Overview
11.4.3 F. Hoffman-La Roche Parkinson’s Disease Therapeutics Introduction
11.4.4 F. Hoffman-La Roche Revenue in Parkinson’s Disease Therapeutics Business (2019-2024)
11.4.5 F. Hoffman-La Roche Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Detail
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Parkinson’s Disease Therapeutics Introduction
11.5.4 GlaxoSmithKline Revenue in Parkinson’s Disease Therapeutics Business (2019-2024)
11.5.5 GlaxoSmithKline Recent Development
11.6 H. Lundbeck A/S
11.6.1 H. Lundbeck A/S Company Detail
11.6.2 H. Lundbeck A/S Business Overview
11.6.3 H. Lundbeck A/S Parkinson’s Disease Therapeutics Introduction
11.6.4 H. Lundbeck A/S Revenue in Parkinson’s Disease Therapeutics Business (2019-2024)
11.6.5 H. Lundbeck A/S Recent Development
11.7 Impax Labs
11.7.1 Impax Labs Company Detail
11.7.2 Impax Labs Business Overview
11.7.3 Impax Labs Parkinson’s Disease Therapeutics Introduction
11.7.4 Impax Labs Revenue in Parkinson’s Disease Therapeutics Business (2019-2024)
11.7.5 Impax Labs Recent Development
11.8 Newron Pharmaceuticals SpA
11.8.1 Newron Pharmaceuticals SpA Company Detail
11.8.2 Newron Pharmaceuticals SpA Business Overview
11.8.3 Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Introduction
11.8.4 Newron Pharmaceuticals SpA Revenue in Parkinson’s Disease Therapeutics Business (2019-2024)
11.8.5 Newron Pharmaceuticals SpA Recent Development
11.9 Novartis AG
11.9.1 Novartis AG Company Detail
11.9.2 Novartis AG Business Overview
11.9.3 Novartis AG Parkinson’s Disease Therapeutics Introduction
11.9.4 Novartis AG Revenue in Parkinson’s Disease Therapeutics Business (2019-2024)
11.9.5 Novartis AG Recent Development
11.10 Orion Corporation
11.10.1 Orion Corporation Company Detail
11.10.2 Orion Corporation Business Overview
11.10.3 Orion Corporation Parkinson’s Disease Therapeutics Introduction
11.10.4 Orion Corporation Revenue in Parkinson’s Disease Therapeutics Business (2019-2024)
11.10.5 Orion Corporation Recent Development
11.11 Teva Pharmaceutical Industries Ltd.
11.11.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.11.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.11.3 Teva Pharmaceutical Industries Ltd. Parkinson’s Disease Therapeutics Introduction
11.11.4 Teva Pharmaceutical Industries Ltd. Revenue in Parkinson’s Disease Therapeutics Business (2019-2024)
11.11.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.12 UCB S.A.
11.12.1 UCB S.A. Company Detail
11.12.2 UCB S.A. Business Overview
11.12.3 UCB S.A. Parkinson’s Disease Therapeutics Introduction
11.12.4 UCB S.A. Revenue in Parkinson’s Disease Therapeutics Business (2019-2024)
11.12.5 UCB S.A. Recent Development
11.13 Livzon Pharmaceutical
11.13.1 Livzon Pharmaceutical Company Detail
11.13.2 Livzon Pharmaceutical Business Overview
11.13.3 Livzon Pharmaceutical Parkinson’s Disease Therapeutics Introduction
11.13.4 Livzon Pharmaceutical Revenue in Parkinson’s Disease Therapeutics Business (2019-2024)
11.13.5 Livzon Pharmaceutical Recent Development
11.14 Haisco Pharmaceutical
11.14.1 Haisco Pharmaceutical Company Detail
11.14.2 Haisco Pharmaceutical Business Overview
11.14.3 Haisco Pharmaceutical Parkinson’s Disease Therapeutics Introduction
11.14.4 Haisco Pharmaceutical Revenue in Parkinson’s Disease Therapeutics Business (2019-2024)
11.14.5 Haisco Pharmaceutical Recent Development
11.15 Jingxin Pharmaceutical
11.15.1 Jingxin Pharmaceutical Company Detail
11.15.2 Jingxin Pharmaceutical Business Overview
11.15.3 Jingxin Pharmaceutical Parkinson’s Disease Therapeutics Introduction
11.15.4 Jingxin Pharmaceutical Revenue in Parkinson’s Disease Therapeutics Business (2019-2024)
11.15.5 Jingxin Pharmaceutical Recent Development
11.16 Dongcheng Biochemicals
11.16.1 Dongcheng Biochemicals Company Detail
11.16.2 Dongcheng Biochemicals Business Overview
11.16.3 Dongcheng Biochemicals Parkinson’s Disease Therapeutics Introduction
11.16.4 Dongcheng Biochemicals Revenue in Parkinson’s Disease Therapeutics Business (2019-2024)
11.16.5 Dongcheng Biochemicals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
